Sax Wealth Advisors LLC Purchases New Stake in Danaher Co. (NYSE:DHR)

Sax Wealth Advisors LLC purchased a new stake in Danaher Co. (NYSE:DHR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,802 shares of the conglomerate’s stock, valued at approximately $450,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC grew its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in Danaher in the fourth quarter worth approximately $29,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the first quarter worth approximately $30,000. Finally, Rakuten Securities Inc. purchased a new position in Danaher in the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 0.2 %

NYSE DHR traded down $0.53 during trading hours on Friday, hitting $268.11. 2,017,772 shares of the company were exchanged, compared to its average volume of 2,898,902. The company has a 50 day moving average of $257.31 and a two-hundred day moving average of $252.28. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $198.59 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 4.62 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DHR. Jefferies Financial Group started coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Robert W. Baird boosted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Barclays increased their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus upped their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 19,085 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total value of $4,866,675.00. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 19,085 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $29,578,725. The disclosure for this sale can be found here. Insiders have sold 66,797 shares of company stock worth $18,039,944 over the last three months. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.